Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

Eli Lilly’s first-in-class non-covalent BTK inhibitor, demonstrated superior overall response rates compared to Imbruvica in ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

Eli Lilly today announced positive top-line results from the Phase III BRUIN CLL-314 clinical trial of Jaypirca ...

Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients ...

Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...

During Jaypirca treatment, call your doctor if you have any symptoms of bleeding listed above or if you have unusual bleeding. But if your symptoms feel life threatening, call 911 right away.

Jaypirca offers a new option for people with MCL. With targeted action on cancer cells, Jaypirca helps control the disease and extend the lives of those living with this rare condition.

Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), ...